309 related articles for article (PubMed ID: 32068483)
1. A High Percent Free Prostate Specific Antigen in the Setting of Biochemical Recurrence after Radical Prostatectomy is Associated with Poorer Outcomes: A Validation Study Using Prospectively Collected Biobank Specimens.
Woon DTS; Herrera-Cáceres JO; Goldberg H; Shiakh H; Whelan E; Nason G; Ajib K; Tan GH; Chandrasekar T; Alhunaidi O; Finelli A; Zlotta A; Berlin A; Diamantis E; Fleshner N
J Urol; 2020 Aug; 204(2):289-295. PubMed ID: 32068483
[TBL] [Abstract][Full Text] [Related]
2. Outcomes and Prognostic Factors in Men Receiving Androgen Deprivation Therapy for Prostate Cancer Recurrence after Radical Prostatectomy.
Ravi P; Karnes RJ; Rangel LJ; Pagliaro LC
J Urol; 2018 Nov; 200(5):1075-1081. PubMed ID: 29709664
[TBL] [Abstract][Full Text] [Related]
3. Do Ultrasensitive Prostate Specific Antigen Measurements Have a Role in Predicting Long-Term Biochemical Recurrence-Free Survival in Men after Radical Prostatectomy?
Sokoll LJ; Zhang Z; Chan DW; Reese AC; Bivalacqua TJ; Partin AW; Walsh PC
J Urol; 2016 Feb; 195(2):330-6. PubMed ID: 26307160
[TBL] [Abstract][Full Text] [Related]
4. The Role of Prostate-specific Antigen Persistence After Radical Prostatectomy for the Prediction of Clinical Progression and Cancer-specific Mortality in Node-positive Prostate Cancer Patients.
Bianchi L; Nini A; Bianchi M; Gandaglia G; Fossati N; Suardi N; Moschini M; Dell'Oglio P; Schiavina R; Montorsi F; Briganti A
Eur Urol; 2016 Jun; 69(6):1142-8. PubMed ID: 26749093
[TBL] [Abstract][Full Text] [Related]
5. Salvage radiotherapy with or without short-term hormone therapy for rising prostate-specific antigen concentration after radical prostatectomy (GETUG-AFU 16): a randomised, multicentre, open-label phase 3 trial.
Carrie C; Hasbini A; de Laroche G; Richaud P; Guerif S; Latorzeff I; Supiot S; Bosset M; Lagrange JL; Beckendorf V; Lesaunier F; Dubray B; Wagner JP; N'Guyen TD; Suchaud JP; Créhange G; Barbier N; Habibian M; Ferlay C; Fourneret P; Ruffion A; Dussart S
Lancet Oncol; 2016 Jun; 17(6):747-756. PubMed ID: 27160475
[TBL] [Abstract][Full Text] [Related]
6. Low detectable prostate specific antigen after radical prostatectomy--treat or watch?
Koulikov D; Mohler MC; Mehedint DC; Attwood K; Wilding GE; Mohler JL
J Urol; 2014 Nov; 192(5):1390-6. PubMed ID: 24859441
[TBL] [Abstract][Full Text] [Related]
7. Does Early Prostate Specific Antigen Doubling Time after Radical Prostatectomy, Calculated Prior to Prostate Specific Antigen Recurrence, Correlate with Prostate Cancer Outcomes? A Report from the SEARCH Database Group.
Teeter AE; Griffin K; Howard LE; Aronson WJ; Terris MK; Kane CJ; Amling CL; Cooperberg MR; Freedland SJ
J Urol; 2018 Mar; 199(3):713-718. PubMed ID: 28870860
[TBL] [Abstract][Full Text] [Related]
8. Mortality and Androgen Deprivation Therapy as Salvage Treatment for Biochemical Recurrence after Primary Therapy for Clinically Localized Prostate Cancer.
Fu AZ; Tsai HT; Haque R; Yood MU; Cassidy-Bushrow AE; Van Den Eeden SK; Keating NL; Smith MR; Zhou Y; Aaronson DS; Potosky AL
J Urol; 2017 Jun; 197(6):1448-1454. PubMed ID: 28007467
[TBL] [Abstract][Full Text] [Related]
9. Prostate-specific antigen level, stage or Gleason score: which is best for predicting outcomes after radical prostatectomy, and does it vary by the outcome being measured? Results from Shared Equal Access Regional Cancer Hospital database.
Mithal P; Howard LE; Aronson WJ; Kane CJ; Cooperberg MR; Terris MK; Amling CL; Freedland SJ
Int J Urol; 2015 Apr; 22(4):362-6. PubMed ID: 25728968
[TBL] [Abstract][Full Text] [Related]
10. Stage T1-2 prostate cancer: a multivariate analysis of factors affecting biochemical and clinical failures after radical prostatectomy.
Kupelian PA; Katcher J; Levin HS; Klein EA
Int J Radiat Oncol Biol Phys; 1997 Mar; 37(5):1043-52. PubMed ID: 9169811
[TBL] [Abstract][Full Text] [Related]
11. What are the factors associated with short prostate specific antigen doubling time after radical prostatectomy? A report from the SEARCH database group.
Teeter AE; Bañez LL; Presti JC; Aronson WJ; Terris MK; Kane CJ; Amling CL; Freedland SJ;
J Urol; 2008 Nov; 180(5):1980-4; discussion 1985. PubMed ID: 18801519
[TBL] [Abstract][Full Text] [Related]
12. Prostate specific antigen at the initial diagnosis of metastasis to bone in patients after radical prostatectomy.
Loeb S; Makarov DV; Schaeffer EM; Humphreys EB; Walsh PC
J Urol; 2010 Jul; 184(1):157-61. PubMed ID: 20483148
[TBL] [Abstract][Full Text] [Related]
13. Serum Lipids prior to Starting Androgen Deprivation Therapy and Risk of Castration Resistant Prostate Cancer and Metastasis: Results from the SEARCH Database.
Dambal S; Howard LE; Allott EH; Aronson WJ; Kane CJ; Amling CL; Cooperberg MR; Terris MK; Freedland SJ
J Urol; 2020 Jan; 203(1):120-127. PubMed ID: 31430247
[TBL] [Abstract][Full Text] [Related]
14. Prostate Specific Antigen Testing after Radical Prostatectomy-Can We Stop at 20 Years?
Ludwig WW; Feng Z; Trock BJ; Humphreys E; Walsh PC
J Urol; 2018 Jan; 199(1):114-119. PubMed ID: 28818527
[TBL] [Abstract][Full Text] [Related]
15. Prostate-specific antigen doubling time subsequent to radical prostatectomy is a predictor of outcome following salvage external beam radiation therapy: a single-centre experience.
Servoll E; Sæter T; Vlatkovic L; Nesland JM; Waaler G; Axcrona K
Scand J Urol; 2015 Jun; 49(3):218-23. PubMed ID: 25428750
[TBL] [Abstract][Full Text] [Related]
16. Prognostic Factors for Biochemical Recurrence More than 10 Years after Radical Prostatectomy.
Liesenfeld L; Kron M; Gschwend JE; Herkommer K
J Urol; 2017 Jan; 197(1):143-148. PubMed ID: 27418452
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of molecular forms of prostate-specific antigen and human kallikrein 2 in predicting biochemical failure after radical prostatectomy.
Wenske S; Korets R; Cronin AM; Vickers AJ; Fleisher M; Scher HI; Pettersson K; Guillonneau B; Scardino PT; Eastham JA; Lilja H
Int J Cancer; 2009 Feb; 124(3):659-63. PubMed ID: 19003994
[TBL] [Abstract][Full Text] [Related]
18. Timing of androgen deprivation therapy and its impact on survival after radical prostatectomy: a matched cohort study.
Siddiqui SA; Boorjian SA; Inman B; Bagniewski S; Bergstralh EJ; Blute ML
J Urol; 2008 May; 179(5):1830-7; discussion 1837. PubMed ID: 18353378
[TBL] [Abstract][Full Text] [Related]
19. Obesity is associated with castration-resistant disease and metastasis in men treated with androgen deprivation therapy after radical prostatectomy: results from the SEARCH database.
Keto CJ; Aronson WJ; Terris MK; Presti JC; Kane CJ; Amling CL; Freedland SJ
BJU Int; 2012 Aug; 110(4):492-8. PubMed ID: 22094083
[TBL] [Abstract][Full Text] [Related]
20. Standardizing the Definition of Biochemical Recurrence after Radical Prostatectomy-What Prostate Specific Antigen Cut Point Best Predicts a Durable Increase and Subsequent Systemic Progression?
Toussi A; Stewart-Merrill SB; Boorjian SA; Psutka SP; Thompson RH; Frank I; Tollefson MK; Gettman MT; Carlson RE; Rangel LJ; Karnes RJ
J Urol; 2016 Jun; 195(6):1754-9. PubMed ID: 26721226
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]